IL-4 inhibits proliferation of renal carcinoma cells by increasing the expression of p21WAF1 and IRF-1

Experimental and Molecular Medicine

Volumn 36, Issue 4, 2004, Pages 372-379

  Yu, Su Jin ^a   Kim, Hyeon Soo ^a   Cho, Sung Won ^a   Sohn, Jeongwon ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

IL 4; Interferon regulatory factor 1; p21WAF1; Renal cell carcinoma

Indexed keywords

CYCLIN DEPENDENT KINASE; INTERFERON REGULATORY FACTOR 1; INTERLEUKIN 4; PROTEIN; PROTEIN P16; PROTEIN P21; PROTEIN P27; PROTEIN P53;

ARTICLE; AUTORADIOGRAPHY; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; PHOSPHORYLATION; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 4644299375     PISSN: 12263613     EISSN: 20926413     Source Type: Journal    
DOI: 10.1038/emm.2004.49     Document Type: Article

References (29)

1. Ackermann LW, Wollenweber LA, Denning GM. IL-4 and IFN-gamma increase steady state levels of polymeric Ig receptor mRNA in human airway and intestinal epithelial cells. J Immunol 1999;162:5112-8
2. Blanchard DA, Affredou MT, Vazquez A. Modulation of the p27kip1 cyclin-dependent kinase inhibitor expression during IL-4-mediated human B cell activation. J Immunol 1997;158: 3054-61
3. Brown MA, Hural J. Functions of IL-4 and control of its expression. Crit Rev Immunol 1997;17:1-32
4. Cheon J, Chung DJ, Kim JJ, Koh SK, Sohn J. Inhibitory effects of interleukin-4 on human renal cell carcinoma cells in vitro: in combination with interferon-α, tumor necrosis factor-α or interleukin-2. Int J Urol 1996;3:196-201
5. Chomczynski P, Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-9
6. Datto MB, Li Y, Panus JF, Howe DJ, Xiong Y, Wang XF. Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. Proc Natl Acad Sci USA 1995;92:5545-9
7. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 1995;82:675-84
8. waf1/cip1 and MAP kinase pathway. Exp Mol Med 2003;35:379-84
9. WAF1/CIP1 gene. Exp Cell Res 1999;246:280-9
10. Giandomenico V, Vaccari G, Fiorucci G, Percario Z, Vannuchi S, Matarrese P, Malorni W, Romeo G, Affabris GR. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-alpha, IFN-beta and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw 1998;9:619-31
11. Goenka S, Youn J, Dzurek LM, Schindler U, Yu-Lee LY, Boothby M. Paired Stat6 C-terminal transcription activation domains required both for inhibition of an IFN-responsive promoter and trans-activation. J Immunol 1999;163:4663-72
12. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991;254:713-6
13. Gooch JL, Lee AV, Yee D. Interleukin 4 inhibits growth and induces apoptosis in human breast cancer cells. Cancer Res 1998;58:4199-205
14. Liu J, Flanagan WM, Drazba JA, Estes ML, Barnett GH, Haqqi T, Kondo S, Barna BP. The CDK inhibitor, p27Kip1, is required for IL-4 regulation of astrocyte proliferation. J Immunol 1997;159:812-9
15. Liu J, Estes ML, Drazba JA, Liu H, Prayson R, Kondo S, Jacobs BS, Barnett GH, Barna BP. Anti-sense oligonucleotide of p21(waf1/cip1) prevents interleukin 4-mediated elevation of p27(kip1) in low grade astrocytoma cells. Oncogene 2000;19:661-9
16. Medema RH, Klompmaker R, Smits VA, Rijksen G. p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. Oncogene 1998;16:431-41
17. Miyazaki M, Ohashi R, Tsuji T, Mihara K, Gohda E, Namba M. Transforming growth factor beta 1 stimulates or inhibits cell growth via down- or up-regulation of p21/Waf1. Biochem Biophys Res Commun 1998;246:873-80
18. Morisaki T, Uchiyama A, Yuzuki D, Essner R, Morton DL, Hoon DS. Interleukin 4 regulates G1 cell cycle progression in gastric carcinoma cells. Cancer Res 1994;54:1113-8
19. Noffz G, Qin Z, Kopf M, Blankenstein T. Neutrophils but not eosinophils are involved in growth supepression of IL-4-secreting tumors. J Immunol 1998;160:345-50
20. Obiri NI, Hillman GG, Haas GP, Sud S, Puri RK. Expression of high affinity interleukin-4 receptors on human renal cell carcinoma cells and inhibition of tumor cell growth in vitro by intedeukin-4. J Clin Invest 1993;91:88-93
21. Ohmori Y, Hamilton TA. IL-4-induced STAT6 suppresses IFN-gamma-stimulated STAT1-dependent transcription in mouse macrophages. J Immunol 1997;159:5474-82
22. KIP1, independent of p53. Oncogene 1998; 17:2393-402
23. Sohn J, Lee CH, Chung DJ, Park SH, Kim I, Hwang WI. Effect of petroleum ether extract of Panax ginseng roots on proliferation and cell cycle progression of human renal cell carcinoma cells. Exp Mol Med 1998;30:47-51
24. Tanaka N, Ishihara M, Kitagawa M, Harada H, Kimura T, Matsuyama T, Lamphier MS, Aizawa S, Mak TW, Taniguchi T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 1994;77:829-39
25. Tepper RI, Pattengale PK, Leder P. Murine interleukin-4 displays potent anti-tumor activity in vivo. Cell 1989;57: 503-12
26. Tepper RI, Coffman RL, Leder P. An eosinophil-dependent mechanism for the antitumor effect of interleukin-4. Science 1992;257:548-51
27. Trejdosiewicz LK, Morton R, Yang Y, Banks RE, Selby PJ, Southgate J. Interleukins 4 and 13 upregulate expression of CD44 in human colonic epithelial cell lines. Cytokine 1998;10:756-65
28. Willman CL, Sever CE, Pallavicini MG, Harada H, Tanaka N, Slovak ML, Yamamoto H, Harada K, Meeker TC, List AF. Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science 1993; 259:968-71
29. Xie RL, Gupta S, Miele A, Shiffman D, Stein JL, Stein GS, van Wijnen AJ. The tumor suppressor interferon regulatory factor 1 interferes with SP1 activation to repress the human CDK2 promoter. J Biol Chem 2003;278:26589-96